Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study
Standard
Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study. / Kellner, M; Nowack, S ; Wortmann, V; Yassouridis, A; Wiedemann, K.
In: PHARMACOPSYCHIATRY, Vol. 49, No. 2, 03.2016, p. 79-81.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study
AU - Kellner, M
AU - Nowack, S
AU - Wortmann, V
AU - Yassouridis, A
AU - Wiedemann, K
N1 - Document Type:Letter
PY - 2016/3
Y1 - 2016/3
N2 - Exposure therapy is an effective cognitive-behavioral treatment for patients with obsessive-compulsive disorder (OCD). However, a further amelioration of symptoms by additional drugs that enhance extinction learning is desirable. An interesting candidate is pregnenolone, which positively modulates NMDA and GABAA receptors in preclinical studies and influences amygdala and prefrontal activity in humans. We present pilot data showing high acceptance and good tolerability of pregnenolone given 2 h before exposure sessions in OCD patients. As per our interim analyses, exposure treatment resulted in significantly improved main outcome parameters, but no effects of pregnenolone vs. placebo pretreatment were detectable thus far.
AB - Exposure therapy is an effective cognitive-behavioral treatment for patients with obsessive-compulsive disorder (OCD). However, a further amelioration of symptoms by additional drugs that enhance extinction learning is desirable. An interesting candidate is pregnenolone, which positively modulates NMDA and GABAA receptors in preclinical studies and influences amygdala and prefrontal activity in humans. We present pilot data showing high acceptance and good tolerability of pregnenolone given 2 h before exposure sessions in OCD patients. As per our interim analyses, exposure treatment resulted in significantly improved main outcome parameters, but no effects of pregnenolone vs. placebo pretreatment were detectable thus far.
KW - Adult
KW - Combined Modality Therapy
KW - Double-Blind Method
KW - Humans
KW - Implosive Therapy
KW - Male
KW - Neurotransmitter Agents
KW - Obsessive-Compulsive Disorder
KW - Pilot Projects
KW - Pregnenolone
KW - Treatment Outcome
KW - Letter
KW - Randomized Controlled Trial
U2 - 10.1055/s-0035-1569371
DO - 10.1055/s-0035-1569371
M3 - Other (editorial matter etc.)
C2 - 26797931
VL - 49
SP - 79
EP - 81
JO - PHARMACOPSYCHIATRY
JF - PHARMACOPSYCHIATRY
SN - 0176-3679
IS - 2
ER -